Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2026-05-19 @ 4:46 PM
Study NCT ID:
NCT06164951
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-12
First Post:
2023-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Sponsor:
QED Therapeutics, a BridgeBio company
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Achondroplasia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Skeletal dysplasia | View |
| None | Endochondral ossification | View |
| None | Quality of life in achondroplasia | View |
| None | Fibroblast growth factor receptor 3 | View |
| None | FGFR3 | View |
| None | Endochondral bone formation | View |
| None | Short-limb disproportionate dwarfism | View |
| None | Dwarfism | View |
| None | Bone disease | View |
| None | Functionality in achondroplasia | View |
| None | Musculoskeletal diseases | View |
| None | Osteochondrodysplasia | View |
| None | Genetic diseases | View |
| None | Long-term treatment | View |
| None | Growth | View |
| None | Annualized height velocity | View |